Impact of Age and Treatment Response on Outcomes in Children with Philadelphia Chromosome-Positive Leukemia
Author Information
Author(s): Virginie Gandemer, Marie-Francoise Auclerc, Yves Perel, Jean-Pierre Vannier, Edouard Le Gall, Francois Demeocq, Claudine Schmitt, Christophe Piguet, Jean-Louis Stephan, Odile Lejars, Marianne Debre, Philippe Jonveaux, Jean-Michel Cayuela, Sylvie Chevret, Guy Leverger, Andre Baruchel
Primary Institution: Department of Pediatric Hematology, University Hospital of Rennes, Rennes, France
Hypothesis
How do age, leukocyte count, and early bone marrow response to chemotherapy affect long-term outcomes in children with Philadelphia chromosome-positive acute lymphoblastic leukemia?
Conclusion
Age, leukocyte count, and early response to treatment are important predictors of long-term outcomes in children with this type of leukemia.
Supporting Evidence
- Complete remission was observed in 72% of the children.
- Children under 10 years with low leukocyte counts had a 100% complete remission rate.
- The five-year disease-free survival rate was 42 ± 9.7%.
Takeaway
This study found that younger children with lower white blood cell counts and a good early response to treatment have a much better chance of surviving leukemia.
Methodology
The study analyzed data from 36 children with Philadelphia chromosome-positive acute lymphoblastic leukemia enrolled in the FRALLE 93 trial, focusing on their age, leukocyte count, and response to chemotherapy.
Limitations
The small sample size may limit the generalizability of the findings.
Participant Demographics
Median age was eight years, with a male-to-female ratio of 1.1.
Statistical Information
P-Value
p<0.005
Confidence Interval
42 ± 9.7%
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website